Tandem Diabetes Care (NASDAQ:TNDM) Rating Increased to Neutral at Bank of America

Bank of America upgraded shares of Tandem Diabetes Care (NASDAQ:TNDM) from an underperform rating to a neutral rating in a research report sent to investors on Friday, MarketBeat reports. The brokerage currently has $30.00 price objective on the medical device company’s stock, up from their previous price objective of $15.00.

TNDM has been the subject of a number of other reports. Truist Financial set a $24.00 target price on Tandem Diabetes Care and gave the company a “hold” rating in a research note on Thursday, December 18th. Robert W. Baird set a $30.00 target price on shares of Tandem Diabetes Care and gave the stock an “outperform” rating in a research note on Tuesday, December 16th. Morgan Stanley set a $23.00 price target on shares of Tandem Diabetes Care and gave the company an “equal weight” rating in a research note on Tuesday, December 2nd. Canaccord Genuity Group set a $35.00 price target on shares of Tandem Diabetes Care and gave the company a “buy” rating in a report on Wednesday, December 17th. Finally, The Goldman Sachs Group reaffirmed a “neutral” rating and set a $25.00 price objective on shares of Tandem Diabetes Care in a report on Friday, January 9th. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, twelve have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $25.50.

Tandem Diabetes Care Price Performance

NASDAQ:TNDM opened at $24.57 on Friday. The company has a quick ratio of 1.90, a current ratio of 2.44 and a debt-to-equity ratio of 2.33. The firm has a market cap of $1.67 billion, a PE ratio of -8.00 and a beta of 1.68. Tandem Diabetes Care has a 12 month low of $9.98 and a 12 month high of $35.12. The company’s 50-day moving average price is $20.91 and its two-hundred day moving average price is $17.01.

Tandem Diabetes Care (NASDAQ:TNDM) last posted its earnings results on Thursday, February 19th. The medical device company reported ($0.01) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.05) by $0.04. The company had revenue of $290.38 million during the quarter, compared to analysts’ expectations of $277.14 million. Tandem Diabetes Care had a negative net margin of 20.17% and a negative return on equity of 70.01%. Tandem Diabetes Care’s quarterly revenue was up 15.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.01 earnings per share. On average, equities analysts anticipate that Tandem Diabetes Care will post -1.68 EPS for the current fiscal year.

Institutional Investors Weigh In On Tandem Diabetes Care

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Freestone Grove Partners LP bought a new position in Tandem Diabetes Care during the third quarter worth about $22,706,000. Ophir Asset Management Pty Ltd acquired a new stake in shares of Tandem Diabetes Care in the 2nd quarter valued at approximately $27,307,000. Assenagon Asset Management S.A. acquired a new stake in shares of Tandem Diabetes Care in the 4th quarter valued at approximately $26,988,000. First Light Asset Management LLC bought a new position in Tandem Diabetes Care during the 4th quarter worth approximately $23,947,000. Finally, BNP Paribas Financial Markets grew its holdings in Tandem Diabetes Care by 468.5% during the fourth quarter. BNP Paribas Financial Markets now owns 1,248,481 shares of the medical device company’s stock valued at $27,442,000 after purchasing an additional 1,028,866 shares during the period.

Key Headlines Impacting Tandem Diabetes Care

Here are the key news stories impacting Tandem Diabetes Care this week:

• Positive Sentiment: Q4 beat on top- and bottom-line metrics — revenue of $290.4M (vs. consensus ~$277M), EPS loss narrower than expected and record quarterly sales and pump shipments; management highlighted margin expansion. Tandem Diabetes Care Announces Fourth Quarter and Full Year 2025 Financial Results and 2026 Financial Guidance
• Positive Sentiment: Market reaction: shares surged intraday after the results and outlook, reflecting investor enthusiasm for the beat, margin momentum and sales growth. Tandem Diabetes Shares Rise 33% On Earnings Beat, Margin Expansion, Growth Outlook
• Positive Sentiment: Analyst upgrades/raise: BofA moved TNDM from Underperform to Neutral and raised its target to $30, and several analysts raised forecasts or price targets after the upbeat quarter. These upgrades support further upside momentum. B of A Securities upgrades Tandem Diabetes Care (TNDM)
• Neutral Sentiment: FY‑2026 revenue guidance (~$1.1B) was reiterated/issued and generally in line with consensus — provides visibility but isn’t a clear upside surprise. Tandem Diabetes Care Announces Fourth Quarter and Full Year 2025 Financial Results and 2026 Financial Guidance
• Neutral Sentiment: New pay-as-you-go (subscription) model announced — could expand long-term addressable market and recurring revenue but timing and transition impact are unclear. Tandem stock rises on Q4 beats, new pay-as-you-go model
• Negative Sentiment: Analyst caution: UBS and other analysts maintained Hold ratings, flagging pay‑go transition uncertainty and competitive headwinds that could limit near-term upside — supporting more conservative views. Tandem Diabetes Care: Solid Q4 Beat Offset by PayGo Transition Uncertainty and Competitive Headwinds Supporting Hold Rating
• Negative Sentiment: Mixed price-target moves: some firms raised targets but others (e.g., Stifel’s $22 target) still imply limited near-term upside versus the current price, underscoring divergent analyst views. Tandem Diabetes price target raised by Stifel

Tandem Diabetes Care Company Profile

Tandem Diabetes Care, Inc (NASDAQ: TNDM), headquartered in San Diego, California, is a medical device company focused on the design, development and commercialization of innovative insulin delivery systems for people with insulin-dependent diabetes. Founded in 2006, the company introduced its first product, the t:slim® Insulin Pump, in 2011 and has since built a portfolio of next-generation pumps featuring touchscreen interfaces, remote software updates and integrated continuous glucose monitoring (CGM) capabilities.

The company’s flagship offering, the t:slim X2® Insulin Pump, is engineered to work with leading CGM sensors and features automated insulin delivery algorithms that adjust basal insulin rates based on real-time glucose trends.